Abstract 221P
Background
The gold standard treatment for the non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guerin (BCG). the instillation of BCG induces an inflammatory response followed by cytokines upregulation and downregulation with a clinical outcome. In this we are targeting the IL1-alpha and TNF-alpha genes and study their genetic polymorphism to elucidate their role in BCG response and tumor recurrence in NMIBC patients.
Methods
The blood samples collected from histopathologically confirmed 224 NMIBC patients from August 2020 to December 2022. The 124 patients were grouped as BCG nonresponsive (BCG-NR) and 100 patients were grouped under BCG-responsive (BCG-R). The classification of group based on the BCG response followed by SWOG protocol. Recurrence/progression of tumor after 6 months consider for the BCG-NR followed by cystoscopy. In contrast patients with no sign of recurrence and progression after 12 months of BCG therapy consider as BCG-R. The DNA was isolated for the genotypic analysis of IL1A -889 C/T-(rs1800587) and TNFA-1031 T/C (rs1799964), in both groups using Taq-Man Probe-based real-time polymerase chain reactions.
Results
In this study, IL1A -889 C, and TNFA, 1031's C allele frequency, were significantly higher in BCG-NR (P <.05). The IL-1 alpha-889 C/T (CC/CT+TT) and TNFA -1031 T/C (TT/TC+CC) genotype expression were shown to be significantly associated with BCG-NR and tumour recurrence (CC/CT+TT; P=.025, TT/TC+CC; P =0.045) as compared to BCG-R in NMIBC.
Conclusions
The genetic polymorphism of the cytokines IL1A -889 C/T (rs1800587) and TNFA-1031 (rs1799964) T/C is significantly susceptible to the recurrence of tumor, BCG response and lead the way for early therapeutic response in NMIBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract